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Abstract: Long-tailed unconventional class I myosin, Myosin 1E (MYO1E) and Myosin 1F (MYO1F)
are motor proteins that use chemical energy from the hydrolysis of adenosine triphosphate (ATP) to
produce mechanical work along the actin cytoskeleton. On the basis of their motor properties and
structural features, myosins perform a variety of essential roles in physiological processes such as
endocytosis, exocytosis, cell adhesion, and migration. The long tailed unconventional class I myosins
are characterized by having a conserved motor head domain, which binds actin and hydrolyzes ATP,
followed by a short neck with an isoleucine-glutamine (IQ) motif, which binds calmodulin and is
sensitive to calcium, and a tail that contains a pleckstrin homology domain (PH), a tail homology
1 domain (TH1), wherein these domains allow membrane binding, a tail homology 2 domain (TH2),
an ATP-insensitive actin-binding site domain, and a single Src homology 3 domain (SH3) susceptible
to binding proline rich regions in other proteins. Therefore, these motor proteins are able to bind
actin, plasma membrane, and other molecules (adaptor, kinases, membrane proteins) that contribute
to their function, ranging from increasing membrane tension to molecular trafficking and cellular
adhesion. MYO1E and MYO1F function in host self-defense, with a better defined role in innate
immunity in cell migration and phagocytosis. Impairments of their function have been identified
in patients suffering pathologies ranging from tumoral processes to kidney diseases. In this review,
we summarize our current knowledge of specific features and functions of MYO1E and MYO1F in
various tissues, as well as their involvement in disease.
Keywords: unconventional myosins; integrins; adaptor molecules; immune cells; cell adhesion;
migration; phagocytosis; host defense; cancer
1. Unconventional Myosins: General Introduction
The myosin protein superfamily found in eukaryotic cells comprises at least 18 classes [1]. Myosins
are motor proteins that bind actin filaments (F-actin) in an adenosine triphosphate (ATP)-regulated
manner. Binding of F-actin promotes ATP hydrolysis by myosin that, in turn, can power movement of
the actin filament or movement of the myosin along the filaments. Structurally, these proteins have an
N-terminal “head”, a middle “neck” region, and a C-terminal “tail” [1].
The N-terminal head is responsible for motor activity, containing a nucleotide binding pocket,
where ATP hydrolysis occurs, and has an actin binding site. Most myosins contain between one and
seven isoleucine-glutamine (IQ) motifs characterized by the IQXXXRGXXXR sequence [2] in the neck
region, and these follow the conserved motor domain sequences directly. Often, calmodulin (CaM)
or CaM-related proteins are associated with stabilizing the α-helical conformation adopted by these
IQ motifs [3,4]. In fact, the IQ motifs and bound light chains form a rigid structure that serves as a
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mechanical lever [5]. The number of IQ motifs determines the length of the lever arm and, therefore,
the step-size and the force of the myosin motor [6]. The C-terminal tail is the region that diverges most
among myosins, having a role in dimerization and being responsible for binding to a diverse array of
partners, targeting each myosin to its particular subcellular location and regulatory function [7].
An evolutionary hypothesis supports that class I and II myosins evolved first among all myosins.
Class II myosins were the first to be discovered and are considered “conventional”, with all other classes
considered “unconventional”. The conventional myosins form large bipolar filaments via tail-directed
homo-oligomerization, whereas the unconventional myosins do not form filaments, although some can
dimerize, and their tails bind directly to the membrane or other proteins [8]. Unconventional myosins
may function to move membranous organelles along actin filaments. Using the “highways and local
roads” analogy, microtubules serve as long range highways for organelle transport powered by the
motor proteins kinesin or dyneins (opposite direction), whereas F-actin serves as short range roads
managed by unconventional myosins [9]. In addition, these myosins can play roles other than cellular
trafficking, such as exocytosis, endocytosis, signal transduction, cell adhesion, and cell migration.
To perform these diverse mechanical tasks, a large number of specialized myosin isoforms have
evolved, which are adapted for high-speed force generation, processive movement over long distances,
tension sensing, and linking signal pathways to motor activity [10].
A striking feature of myosin motors is the great variability in the length of the neck region formed
by the α-helix of IQ motifs, which are stabilized by binding light chains of the calmodulin family.
Variations in these light chain motifs and in the length and stiffness of the myosin appear to affect the
mechanical properties of the myosin motor [10] and give rise to the different classes of unconventional
myosins [11].
In this review, we will focus on class I unconventional myosins, particularly regarding our current
knowledge of how long-tailed forms function and are involved in disease.
2. Class I Unconventional Myosins
Class I myosins are the largest group of unconventional myosins and are evolutionary ancient,
existing in a wide range of species from yeast to vertebrates [12]. Type I myosin functions as a monomer,
with one end connecting to lipids in the plasma membrane and the other connecting to cortical actin
(i.e., the network of actin filaments underneath the plasma membrane). When myosin type I connects
to cortical actin and hydrolyzes ATP, it tucks in and moves along the actin filament (to the plus end)
and creates tension but reinforces the connection between the plasma membrane and cortical actin,
enabling the cell to support the plasma membrane [13].
Mice and humans have a total of eight class I heavy-chain myosin genes, of which six encode
short-tailed forms (Myosin 1A, -B, -C, -D, -G, and -H) and two encode long-tailed forms (MYO1E
and MYO1F) [14]. MYO1B and MYO1E are expressed in most cells, but MYO1A and MYO1F are
more restricted to the intestines and hematopoietic cells, respectively [15]. Myosin class I associates
with between one and six calmodulins, and all have either a pleckstrin homology (PH) domain or a
basic tail homology 1 domain (TH1) in their tail that are thought to affect membrane interaction [16].
The PH domain bears the KXn(K/R)XR (where K is lysine, R arginine, X any amino acid) canonical
sequence for binding to phosphoinositides and is located between the β1 and β2 sheets within the TH1
domain [17]. TH1 is basic in charge and may effect interactions with negatively charged phospholipids.
The lipid specificities and function in membrane interaction are highly dependent on the isoform [11].
The long-tailed forms also contain a proline-rich tail homology 2 domain (TH2) domain; this domain
contains an ATP-insensitive actin binding site [18] and a large number of basic amino acids suitable
for binding membrane phospholipids [19].The C-terminal end of the tail has a single Src homology 3
(SH3) domain, which binds to proline rich regions, particularly proteins carrying the PXXP (where P is
a proline and X any amino acid) motif [20] (Figure 1).
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Figure 1. Schematic representation and structure of human unconventional type 1 myosins. All 
myosins comprise conserved motor heads (orange), different numbers of isoleucine-glutamine (IQ) 
motifs (green), a helical region (pink), IQ and helical extension comprising the neck region, and 
distinct tails with various functional domains. Long-tailed myosins, such as MYO1E and MYO1F, also 
have an Src homology 3 domain (SH3) domain for protein–protein interaction. 
3. The Long-Tailed Unconventional Class I Myosins 
MYO1E and MYO1F are long-tailed class I myosins that have similar structures and patterns of 
tissue expression. Although their similarities reveal some convergences between the two myosins, 
they have important differences that result in discrepancies in cellular function and their role in 
diseases. Both MYO1E and MYO1F are expressed mainly in immune system cells. MYO1E has a 
wider expression pattern than MYO1F, and is highly present in the spleen, mesenteric lymph nodes, 
and lung, as well as to a lesser extent in the intestines and skin. By contrast, MYO1F is mostly 
expressed in the spleen, mesenteric lymph nodes, thymus, and lungs [15]. Lymphoid tissues, natural 
killer cells, macrophages, and dendritic cells express considerable levels of both MYO1E and MYO1F, 
with selective expression reported in B cells and neutrophils, respectively [15]. Lately, MYO1F has 
also been reported as being expressed in mast cells [21]. 
3.1. MYO1E and MYO1F in Neutrophils 
Neutrophils play an important role in innate immunity, and their extravasation in response to 
an infection or injury is the factor that contributes fastest to the elimination of a pathogen and 
subsequent wound healing [22,23]. Neutrophil recruitment to the site of inflammation must be 
carefully regulated because deficient or excessive levels can have severe pathological consequences. 
As reported recently, neutrophils can contribute to tissue injury by amplifying the inflammatory 
response and direct release of toxic effectors and assist in the development of many noninfectious 
diseases, such as lung injury, autoimmune diseases, and cancer [24]. Neutrophil extravasation 
implies, among other things, proper adhesion to the vascular endothelium and migration to the 
infected tissue, which depends on actin remodeling and the regulated action of myosins [25,26]. 
Motile neutrophils exhibit a polarized morphology characterized by the formation of leading edge 
pseudopods and a highly contractile cell rear known as the uropod [23].  
Figure 1. Schematic representation and structure of human unconventional type 1 myosins. All myosins
comprise conserved motor heads (orange), different numbers of isoleucine-glutamine (IQ) motifs
(green), a helical region (pink), IQ and helical extension comprising the neck region, and distinct tails
with various functional domains. Long-tailed myosins, such as MYO1E and MYO1F, also have an Src
homology 3 domain (SH3) domain for protein–protein interaction.
3. The Long-Tailed Unconventio al Class I Myosins
MYO1E and MYO1F are long-tailed class I myosins that have similar structures and patterns of
tissue expression. Although their similarities reveal some convergences between the two myosins,
they have important differences that r sult in discrepancies in c llular function and their role in
di eases. Both MYO1E and MYO1F are expressed mainly in immu e syst m cells. MYO1E has a
wider expression p ttern than MYO1F, and is highly present in the spleen, mesenteric lymph n des,
and lung, as well as to a lesser extent in th intestines and skin. By contrast, MYO1F is mostly expressed
in th spleen, mesen eric lymph nodes, thymus, and lungs [15]. Lymphoid tissu s, natural kill r
cells, macrophag s, nd dendritic c lls express co siderable levels of both MYO1E and MYO1F, with
s lective expression r ported in B cells and neutrophils, respectively [15]. Lately, MYO1F has also been
reported a being expres ed in mast cells [21].
3.1. MYO1E and MYO1F in Neutrophils
Neutrophils play an important role in innate immunity, and their extravasation in response
to an infection or injury is the factor that contributes fastest to the elimination of a pathogen and
subsequent wound healing [22,23]. Neutrophil recruit ent to the site of inflammation must be carefully
regulated because deficient or excessive levels can have severe pathological consequences. As reported
recently, neutrophils can co tribute to tissue injury by amplifying the inflammatory response and direct
release of toxic effectors and assist i the development of many noninfectious diseases, such as lung
injury, autoimmune diseases, and cancer [24]. Neutrophil extravasation i lies, among other things,
proper adhesion to the vascular endothelium and migratio to the infected tissue, which depends n
actin remodeling and the regulated action of myosins [25,26]. Motile neutrophils ex ibit a polarized
morphology characterized by the formation of leading edge pseudopods and a highly contractile cell
rear known as the uropo [23].
Altho gh MYO1E is barely expressed in neutrophils, it has been shown to be required for their
efficient extravasation [27]. Recently, MYO1E-deficient neutrophils were shown to have diminished
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arrest, spreading, uropod formation, and chemotaxis due to defective actin polymerization and
integrin activation. Indeed, β2 integrin-mediated rolling and adhesive interactions are affected in
MYO1E knock out neutrophils. This phenotype resulted in increased rolling velocity, decreased
firm adhesion, aberrant crawling, and strongly reduced transmigration. Thus, MYO1E appears to
regulate the adhesive interactions of neutrophils with the vascular endothelium needed for neutrophil
extravasation, reducing both 2D and 3D migration [27].
MYO1F is highly expressed in neutrophils, where it plays an essential role in their migration.
Neutrophils from MYO1F-deficient mice showed stronger adhesion to integrin ligands, including
intercellular adhesion molecule-1 and fibronectin, and most of this adhesion was mediated by β2
integrin. Indeed, MYO1F-deficient neutrophils exhibited high levels of cell-surface β2 integrin [15].
Given that regulated integrin-mediated adhesion to the vascular endothelium is critical to neutrophil
migration to infected tissue, MYO1F-deficient mice unsurprisingly presented higher mortality when
exposed to infection by Listeria monocytogenes. Similarly, effects on defective neutrophil migration have
been found in SH3-binding protein 2 (3BP2)-knockout mice, which also resulted in a higher mortality
to Listeria infection [28]. Interestingly, the adaptor protein 3BP2 has been reported to be a ligand of
MYO1F [21]. However, the mechanistic details of how these binding partners regulate neutrophil
migration remains to be elucidated.
In the analysis of neutrophil migration in 3D experiments, transmigration and migration in
collagen networks showed that neutrophil extravasation into the tissue was also severely compromised
in MYO1F-deficient mice due to a defective dynamic deformation of the nucleus [29]. For successful
cell migration in these contexts, the nucleus must undergo defined changes in position and shape that
are dependent on cytoskeletal dynamics and the mechanical linkage between actin filaments and the
nuclear membrane. MYO1F was found to be enriched at the rear and the front ends of the elongated
nucleus during the initiation and deformation phases, and it was probably involved in pushing and/or
pulling the nucleus through the constriction sites, transmitting force from the cytoskeleton to the inside
of the nucleus [29]. Together, these results support the contention that MYO1F is key to host defenses
by facilitating neutrophil migration to the site of inflammation.
The impaired neutrophil migration observed in MYO1E- and MYO1F-deficient mice have distinct
molecular foundations. In the case of MYO1F, its absence did not lead to reduced neutrophil rolling or
adhesion on endothelial cells, a phenomenon that was described in MYO1E-deficient neutrophils [27].
MYO1F-mediated neutrophil migration has been reported to be critical to acute neuroinflammation in
ischemic stroke, directly affecting outcomes. During the acute phase of a stroke, neutrophils from the
peripheral blood are the first to arrive in the ischemic brain, which then attracts other immune cells
that exacerbate neuroinflammation in the ischemic tissue [30]. Although further research on dissecting
the ligand partners and mechanisms will be important to unraveling the causes of the functional
differences between MYO1E and MYO1F, data currently points to long-tailed class I myosins having a
key role in neutrophil function.
3.2. MYO1E and MYO1F in Macrophages
Phagocytosis of invading pathogens and/or cellular debris are processes carried out mainly
by macrophages in the different tissues. These events needed for host defense, tissue remodeling,
and repair require significant changes in phagocyte morphology that accounts for the coordinated
participation of a plethora of molecules involved in adhesion, membrane arrangements, and actin
cytoskeleton dynamics [31].
The sensing of infectious danger by macrophages through the ligation of toll-like receptors (TLR)
triggers fast and robust cytoskeletal changes, including an integrin-mediated spreading response that
is dependent on actin polymerization [32,33]. MYO1E, along with its closely related family member
MYO1F, are strongly serine phosphorylated in the tail domain after triggering TLR4, with several sites
located in the TH2 domain and one threonine in the PH domain within the TH1 region [34]. Although
these data indicate a regulatory mechanism in the action of these myosins in macrophage function
Int. J. Mol. Sci. 2020, 21, 2555 5 of 13
against pathogens, no further evidence has been reported. The function of these two myosins seems
to be redundant in contributing to lipopolysaccharide-triggered macrophage spreading [35]. In the
context of macrophages as antigen presenting cells, MYO1E may control the exocytosis of cytoplasmic
vesicles to the plasma membrane (containing major histocompatibility complex class II) through the
interaction with the ARF7 effector protein (ARF7EP; also known as ARL14) and contributing to antigen
presentation [36]. Consequently, the lack of MYO1E correlates with a deficient antigen-specific T cell
proliferation [35].
More recently, it has been reported that MYO1F is induced in colonic macrophages and positively
influences αVβ3-integrin accumulation [37]. This process enhances intercellular adhesion between
macrophages and stimulates a proinflammatory (M1) phenotype by inducing integrin-linked kinase
(ILK)/Protein Kinase B (AKT)/ (mammalian Target of Rapamycin (mTOR) signaling, which, in turn,
induces Signal transducers and activators of transcription(STATS), STAT1 and STAT3 activation.
Consequently, macrophages lacking MYO1F show reduced intercellular association via integrin-β3 and
do not commit to the M1 phenotype. Furthermore, MYO1F upregulation leads to enhanced secretion
and production of interleukin-1β and, accordingly, lack of MYO1F has been shown to result in reduced
inflammation in a colitis model [37].
More recent data have shown that MYO1E and MYO1F are both required for efficient Fc receptors
(FcR)-mediated phagocytosis [38]. Engagement of FcR on the phagocyte with antibodies on the
target surface induces phagocytic cup formation (an actin-rich cup-like structure) to engulf the target.
The plasma membrane is extended around the phagocytic cup and the ensuing closure of the cup
results in phagosome formation where further processing of the target will occur. All these steps require
active cytoskeleton dynamics and mechanical forces [31,39]. Macrophages form circular dynamic actin
waves in the extending arms of the phagocytic cup, an event linked to phagocytosis [40]. MYO1E and F
are reported as being recruited to the phagocytic cup, and they are found to be enriched in the punctate
actin that makes up the wave. This location is dependent on the actin-binding via the motor domain, as
well as the TH2 domain (via phospholipid membrane binding through the basic amino acids present
in this domain), and thus it is exclusive to long-tailed unconventional class I myosins. The study of
Barger et al. suggests a model where MYO1E and F function to tether the plasma membrane to the
actin to successfully anchor the target to the cell, allowing actin polymerization within the cup to
progress and finish internalization. The absence of MYO1E-F alters the local membrane tension and
actin polymerization, resulting in an actin-dense phagocytic cup that leads to a slower closure of the
phagocytic cup and lower rate of phagocytosis [38].
3.3. MYO1F in Mast Cells
Mast cells are essential effector cells in both the innate and adaptive arms of the immune system.
They rely on their ability to migrate to inflammatory sites and release specific mediators stored
in preformed granules or synthesized de novo if they are to function [41]. These processes are
highly regulated by signaling events and precise cytoskeletal dynamics. Mast cells are resident in
tissues, meaning that their migration as progenitors is needed before recruitment to inflammatory
target tissue is possible [42]. Increased numbers of mast cells in inflamed tissue occur not only
in bacterial and parasitic infection, but also in asthma and urticarial [43]. In these settings, mast
cells recognize chemotactic stimuli and trigger signaling cascades that lead to integrin activation,
adhesion, and migration. Stem cell factor (the tyrosine-protein kinase KIT receptor ligand) is the key
chemotactic factor in mast cell proliferation, survival, homing, and migration [44].Recently, our group
showed that MYO1F is expressed in mast cells, where it colocalizes with the cortical actin ring [21].
We also found that 3BP2 interacts with MYO1F. The cytoplasmic adaptor protein 3BP2 contains a
PH domain, SH3-binding proline-rich regions, and a C-terminal SH2 domain [45], and it has roles
in mast cell degranulation [46], survival [47], and migration [21]. Interestingly, the 3BP2–MYO1F
interaction is modulated by KIT receptor signaling, possibly by the increase of phosphoinositide
3-kinase (PI3K) activity and consequently the production of phosphatidylinositol-3,4,5-triphosphate,
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ligands of the PH domains contained in 3BP2 and MYO1F, resulting in a major recruitment of both at
the plasma membrane.
Consequently, KIT inhibition alters MYO1F and 3BP2 translocation to the membrane,
and subsequently colocalization of both molecules [21]. In the context of KIT signaling, the absence
of MYO1F or 3BP2 impairs integrin-mediated mast cell adhesion and migration. MYO1F silencing
specifically achieves this by decreasing the expression of two integrin β chains on the cell surface,
β1 (Cluster of Differentiation 29) and β7, usually coupled with the α4 chain [21].
These data point to a model where MYO1F could serve as a link between the actin cytoskeleton
and the localization and function of integrin in the cell membrane after the activation of KIT receptors
(Figure 2). We further hypothesize that MYO1F could modulate integrin by regulating the cortical
actin mesh, on the basis of evidence that the cortical actin ring is necessary for mast cell migration [48].
Myo1E has not been reported in mast cells to date.
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Figure 2. The role of MYO1F in mast cell migration. In resting conditions, mast cells express tyrosine-
protein kinase KIT receptor and different integrins on the cell membrane. The actin cytoskeleton and 
MYO1F are distributed along the cell membrane and in the cytoplasm, whereas Src homology 3 
domain (SH3)-binding protein 2 (3BP2) is mostly found in the cytoplasm. Activation of the KIT 
receptor initiates actin remodeling, which generates the leading edge (consisting of actin filaments) 
necessary for cell movement. MYO1F is necessary for the secretion and localization of activated 
integrin molecules that will induce adhesion to the extracellular matrix and aid cell migration. 
3.4. MYO1E in B Lymphocytes 
The migration of lymphocytes to lymph nodes is a crucial step for the immune response to 
encounter antigens [49]. The adhesion of lymphocytes to high endothelial venules and their migration 
through that network are regulated by adhesins, integrins, and chemokines, as well as the actin 
cytoskeleton [50,51]. In lymphocytes, the expression of long-tailed unconventional class I myosins 
appears to be restricted to MYO1E. Its expression is especially high in B lymphocytes, but until 
recently, its role has been elusive. Consistent with its role in other immune cells, MYO1E has been 
reported as being critical for the recruitment and adhesion of activated B cells to the inguinal lymph 
node. Rolling and cellular transmigration are affected in activated B lymphocytes from MYO1E KO 
mice by a reduction of cell spreading (a mechanism used to maximize cellular contact to allow 
transmigration) due to a lack of CARMIL (capping protein, Arp2/3, and Myosin-I linker), which is 
important in cell migration and a ligand of MYO1E [52,53]. On the other hand, activated B cells from 
MYO1E KO mice have reduced levels of LFA-1 (Lymphocyte Function associated Antigen 1), CD44, 
and VLA-4 (Very Late Antigen-4) at the plasma membrane, suggesting that MYO1E is playing a role 
in vesicle trafficking of these adhesion molecules. The molecular mechanism involves the focal 
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tyrosine-protein kinase KIT receptor and different i tegrins on the cell membrane. The actin cytoskeleton
and MYO1F are distributed along the cell membrane and in the cytoplasm, whereas Src ho ology 3
do ain (SH3)-binding protein 2 (3BP2) is mostly found in the cytoplasm. Activation of the KIT receptor
initiates actin remodeling, which generates the leading edge (consisting of actin filaments) necessary for
cell movement. MYO1F is necessary for the secretion and localization of activated integrin molecules
that will induce adhesion to the extracellular matrix and aid cell igration.
3.4. MYO1E in B Lymphocytes
The migration of lymphocytes to lymph nodes is a crucial step for the immune response to
encounter antigens [49]. The adhesion of lymphocytes to high endothelial venules and their migration
through that network are regulated by adhesins, integrins, and chemokines, as well as the actin
cytoskeleton [50,51]. In lymphocytes, the expression of long-tailed unconventional class I myosins
appears to be restricted to MYO1E. Its expression is especially high in B lymphocytes, but until recently,
its role has been elusive. Consistent with its role in other immune cells, MYO1E has been reported
as being critical for the recruitment and adhesion of activated B cells to the inguinal lymph node.
Rolling and cellular transmigration are affected in activated B lymphocytes from MYO1E KO mice by a
reduction of cell spreading (a mechanism used to maximize cellular contact to allow transmigration)
due to a lack of CARMIL (capping protein, Arp2/3, and Myosin-I linker), which is important in cell
migration and a ligand of MYO1E [52,53]. On the other hand, activated B cells from MYO1E KO
mice have reduced levels of LFA-1 (Lymphocyte Function associated Antigen 1), CD44, and VLA-4
(Very Late Antigen-4) at the plasma membrane, suggesting that MYO1E is playing a role in vesicle
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trafficking of these adhesion molecules. The molecular mechanism involves the focal adhesion kinase
(FAK), which has a role in integrin-mediated signal transduction [54]. FAK activity is reduced in
activated B lymphocytes from MYO1E KO mice as well as AKT and the RAC-1 GTPase, both dependent
on PI3K activity [53]. An explanation for the reduction in FAK activity in the MYO1E KO model may
be by the fact that MYO1E interacts with FAK and promotes its autophosphorylation upon stimulation
with CXCL12 in activated B cells [53]. This MYO1E–FAK interaction has been reported previously in
melanoma, which we discuss in the next section.
4. Class I Unconventional Long-Tailed Myosins in Diseases
Considering the role of long-tailed myosin, any improper function can lead to aberrant cell
adhesion and migration, thereby compromising homeostasis and resulting in pathology. Altered
function has been associated with various diseases.
4.1. MYO1E and MYO1F in Cancer
Several recent studies have focused on the roles of myosins in cell invasion and migration and on
their potential role as tumor suppressors or activators in cancer [55].
4.1.1. MYO1E
MYO1E directly interacts with FAK, a protein involved in many biological processes, including
cancer [56]. This interaction, which occurs through a FERM-kinase linker domain, induces
conformational changes and Y397 autophosphorylation that is essential for in vivo FAK activity.
Once active, FAK accumulates in the nucleus, where it causes changes in gene expression (osteopontin
and other fibronectin-type matrix genes) that are often seen in aggressive cancers. The increase
of FAK activity and consequently of its target genes has been directly associated with metastatic
events [57,58]. FAK and MYO1E interaction can be involved in the molecular basis of tumoral processes
associated with FAK-dependent activity, such as melanoma. Indeed, the levels of phosphorylated
nuclear phosphor Y379 FAK have been found to be high in patient-derived tissues and cell lines [56].
Moreover, both FAK and MYO1E have been found to promote mammary tumor progression [59–61].
The role of MYO1E in breast cancer has become more evident in recent years. An increase of
MYO1E expression was found as a gene signature in patients with poor outcome in basal-like breast
cancer (BLBC) [62]. This is a particularly aggressive molecular breast cancer subtype characterized by
a specific gene cluster expressed by epithelial cells located in the basal or outer layer of the mammary
gland. BLBC is a major clinical challenge because of its high relapse and prevalence in young women.
More recently, a meta-analysis of human data has shown a correlation between high MYO1E expression
and poor prognosis in BLBC and grade-1 breast cancer [61]. To delve into the role of MYO1E in breast
cancer, studies have been performed with MYO1E knockout mice carrying the MMTV-PyMT transgene
(mouse mammary tumor virus–polyoma middle T antigen). MMTV is a promoter that is expressed
exclusively in mammary epithelium, thus conferring tissue specificity in this accepted mouse breast
cancer model [63]. MYO1E KO have shown reduced cell proliferation and enhanced cell differentiation
compared with MYO1E wild-type controls. The molecular mechanism underlying this effect could
be related to the cell–cell junction dynamics. Although, the authors did not find differences in the
localization of structural components of cell–cell junctions, the functional data provides evidence
of reduced cell permeability in the MYO1E KO mice. Thus, the cell–cell junction in MYO1E WT is
different compared with MYO1E KO, and may account for the distinct tumor morphology, proliferation,
differentiation, and progression [61]. Further analysis will be needed in order to understand the
molecular basis.
MYO1E is a component of the invadosome core that contributes to regulating their dynamics [64].
Invadosomes are actin-rich adhesion structures containing a dense meshwork of actin filaments at their
center, as well as a ring of adhesion adapter proteins representing a site of intense matrix degradation by
tumor cells. These play an important role in tumor cell invasion [65,66]. Targeting MYO1E activity may
Int. J. Mol. Sci. 2020, 21, 2555 8 of 13
have therapeutic potential by preventing the metastasis of tumor cells that depend on invadosomes for
migration. Furthermore, MYO1E expression may be used as a biomarker of highly invasive tumors.
4.1.2. MYO1F
A recent study has shown that mutated MYO1F alters the mitochondrial network and induces
tumor proliferation in thyroid cancer [67]. This arises due to a mutated MYO1F gene at the TCO locus
(Gly134Ser) that leads to increased oncogenic potential in vitro in terms of cell growth and invasion.
The mitochondrial membrane potential was similar in mutant versus control cells, suggesting that the
mitochondria were still functional. However, in the mutant cell lines, analysis by live-cell visualization
revealed that the mitochondria appeared as separate rod-shaped organelles with increased mass that
produced significantly more intracellular and extracellular reactive oxygen species. How MYO1F
regulates the mitochondrial network needs to be addressed.Several somatic mutations in MYO1F
related to different types of cancer have been found in genetic databases [67]. One example is the fusing
of the mixed lineage leukemia gene with the MYO1F gene, which has been described as recurrent
in infant acute monocytic leukemia [68,69]. Interestingly, a VAV1-MYO1F fusion protein (where the
SH3 domain of VAV1 is replaced by the SH3 domain of MYO1F) has been found in a heterogeneous
non-Hodgkin peripheral T cell lymphoma. The aberrant fusion protein increases the oncogenic ability
of VAV1 and is associated with a poor prognosis. What derives from these data is the fact that
the MYO1F SH3 domain, possibly by recruitment of proteins, increases the VAV1-dependent tumor
activity [70,71].
4.2. MYO1E in Kidney Diseases
MYO1E regulates actin reorganization during cell–cell adhesions in podocytes, major components
of the glomerular filtration barrier. The podocyte actin cytoskeleton and its highly specialized cell–cell
junctions (also called slit diaphragm complexes) play key roles in controlling glomerular filtration.
MYO1E expression is enriched in these slit diaphragm complexes [72] and is recruited to the newly
formed cell–cell junctions [73]. Moreover, MYO1E functions by linking the plasma membrane and actin
filaments early in the process of cytoskeletal rearrangements in the newly stablished cell–cell contact in
renal podocytes. To accomplish this, the TH1 and TH2 domains target MYO1E to the cell junctions,
and the SH3 domain serves as an effector that interacts with the tight junction protein ZO-1 [74],
therefore regulating the formation and dynamics of cell–cell junctions and compromising tissue
permeability [73]. Consistent with this, MYO1E KO and podocyte-specific MYO1E KO show defects
in podocyte organization and disruption of glomerular filtration, showing an increase in proteinuria,
complement and IgG deposition. Interestingly, the observed renal defects do not seem to be immune
mediated but rather result from impaired podocyte functions [75,76]. Furthermore, MYO1E mutations
are associated with childhood-onset, glucocorticoid-resistant, focal segmental glomerulosclerosis that
manifests as nephrotic syndrome with hypoalbuminemia, proteinuria, hyperlipidemia, and edema [77].
MYO1E may function as a linker between the plasma membrane phospholipids, protein components
of cell–cell junctions, and actin filaments, maintaining the integrity of the glomerular filtration barrier
for proper kidney function.
4.3. MYO1F in Hearing Loss
Myosins are necessary for hearing because they contribute both to the structure of stereocilia
found in hair cells of the inner ear [78] and to auditory mechanotransduction. Specifically, MYO1F
is expressed in the inner ear [15], and mutations in its gene may be responsible for nonsyndromic
deafness [79,80]. Such mutations have been detected in the head domain, where they could affect
ATPase activity or the actin binding process. However, it is not known whether hearing loss occurs
due to an increased susceptibility to infection or to an abnormal neutrophil response, leading to the
production of reactive oxygen species and the subsequent involvement of proteolytic enzymes and
antimicrobial proteins.
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5. Conclusions and Perspectives
Long-tailed unconventional class I myosins are involved in several physiological roles from
endocytosis to cell migration, and these must be finely regulated to avoid pathology. The presence
of specific domains, such as SH3 in their tail region, appears to be responsible for their individual
cellular functions by facilitating association with adaptors and other binding proteins. In this way,
the interaction between MYO1F and 3BP2 links the KIT receptor, which is involved in mast cell migration
to the actin cytoskeleton. Alternatively, the interaction between MYO1E and FAK modulates the
activity of the latter, and is important in cell proliferation, survival, and cellular motility. Both MYO1F
and MYO1E regulate actin cytoskeleton dynamics and allow biological events such as phagocytosis for
the clearance of pathogens, dead cells, and aberrant proteins, thereby promoting health. Cell migration
is also critical for fighting infection and for allowing tumor cells to metastasize. Improving our
understanding of the function and regulation of MYO1F and MYO1E could lead to developments that
affect diseases, ranging from immune system alterations to cancer. Ultimately, it is hoped that we may
identify specific myosin inhibitors or activators that have therapeutic potential.
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